1. Advances in conjunctival melanoma: clinical features, diagnostic modalities, staging, genetic markers, and management.
- Author
-
Zeiger JS, Lally SE, Dalvin LA, and Shields CL
- Subjects
- Humans, Genetic Markers, Disease Management, Conjunctival Neoplasms genetics, Conjunctival Neoplasms diagnosis, Conjunctival Neoplasms therapy, Melanoma genetics, Melanoma diagnosis, Melanoma therapy, Neoplasm Staging, Biomarkers, Tumor genetics
- Abstract
Conjunctival melanoma, a rare malignancy of the ocular surface, is increasing in incidence. When small, straightforward excision with "no touch" surgery and cryotherapy at an experienced centre can provide excellent outcomes. When advanced, management is more complex and highly individualized. The risk of metastatic disease from conjunctival melanoma is as high as 30% and depends on tumour origin, American Joint Committee on Cancer (AJCC) classification, biomarkers, and perhaps most important, management technique. Metastatic disease can result in melanoma-associated death. Therefore, early detection and prompt directed treatment at an experienced centre are important for protection from metastasis. In this review, we provide an update on conjunctival melanoma clinical features, diagnostic modalities, AJCC staging, genetic markers, and the most critical, controlled management with minimization of tumour seeding. We detail the new era of characterization of conjunctival melanoma with molecular biomarkers that predict melanoma prognosis. This could lead to precision medicine with targeted approaches to specific mutations that improve patient survival. As we work together, the field of conjunctival melanoma is moving forward., (Copyright © 2023 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF